Myeloproliferative Neoplasms | Specialty

PV Treatment Landscape Balancing Effective Regimens With QOL Challenges

April 18th 2018

Jeanne M. Palmer, MD, discusses the current treatment landscape for patients with polycythemia vera and highlighted the impact that ruxolitinib has had on the second-line treatment setting.

JAK Signaling Remains a Promising Target in Myeloproliferative Neoplasms

April 10th 2018

Srdan Verstovsek, MD, PhD, discusses the rationale for targeting JAK signaling, new drugs under study for this pathway, and clinical challenges associated with these therapies.

Novel Approaches Show Promise in Targeting JAK Pathway

February 12th 2018

Dysregulation of the JAK pathway plays a role in the development of numerous tumor types; it is particularly central to the pathophysiology of myelofibrosis and has long been recognized as a potentially valuable therapeutic target in that malignancy.

Ropeginterferon Alfa-2b Demonstrates Durable Activity in Polycythemia Vera

December 21st 2017

Two-year findings from the follow-up phase III CONTI-PV randomized trial showed that ropeginterferon alfa-2b, a novel pegylated formulation of interferon alfa-2b, reached a significantly higher rate of complete hematologic response versus hydroxyurea in patients with polycythemia vera.

Ruxolitinib Retains Benefit in Polycythemia Vera With Longer Follow-Up

December 20th 2017

Responses to ruxolitinib (Jakafi) in patients with polycythemia vera were maintained by a majority of primary responders at 4 years’ follow-up.

Dr. Pemmaraju on Clinical Trial Results of LCL161 in High-Risk Myelofibrosis

December 13th 2017

Naveen Pemmaraju, MD, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the clinical trial results for LCL161 in patients with intermediate or high-risk myelofibrosis.

Dr. Mims Discusses Momelotinib in Myelofibrosis

November 10th 2017

Alice S. Mims, MD, assistant professor of medicine, The Ohio State University Comprehensive Cancer Center, discusses momelotinib in patients with myelofibrosis.

Dr. Stein Discusses Changes to the NCCN Guidelines in MPNs

October 31st 2017

Brady L. Stein, MD, associate professor of medicine, Feinberg School of Medicine, Northwestern University, discusses changes to the National Comprehensive Cancer Network (NCCN) guidelines in myeloproliferative neoplasms (MPNs).

Emerging Treatments Show Promise in Myelofibrosis

October 27th 2017

Alice Mims, MD, provides updates on the field of myeloproliferative neoplasms, with a focus on myelofibrosis.

Dr. Mims on the Current Challenges With Myelofibrosis

October 26th 2017

Alice S. Mims, MD, assistant professor of medicine, Ohio State University Comprehensive Cancer Center, discusses the current challenges with myelofibrosis.

Mesa Highlights Guideline Updates in Myeloproliferative Neoplasms

October 11th 2017

The National Comprehensive Cancer Network guidelines for the management of polycythemia vera and essential thrombocythemia have been updated to create a more uniform system of management for healthcare providers to follow in clinical practice.

Dr. Mesa on Guideline Updates in Polycythemia Vera and Essential Thrombocythemia

October 8th 2017

Ruben Mesa, chair of the Division of Hematology and Medical Oncology at Mayo Clinic, discusses the guideline updates in polycythemia vera and essential thrombocythemia.

Treatment of Primary Myelofibrosis

May 31st 2017

Primary Myelofibrosis Disease State

May 31st 2017

Emerging Therapies for Polycythemia Vera

May 31st 2017

Failure of Polycythemia Vera Control with Phlebotomy

May 31st 2017

Response to Ruxolitinib Therapy for Polycythemia Vera

May 31st 2017

Relapsed or Refractory Polycythemia Vera

May 31st 2017

Practical Considerations of Polycythemia Vera Treatment

May 31st 2017

Therapeutic Options for Polycythemia Vera

May 31st 2017